Sanofi Debt Issuance/Retirement Net - Total 2010-2025 | SNY
Sanofi annual/quarterly debt issuance/retirement net - total history and growth rate from 2010 to 2025. Debt issuance/retirement net - total can be defined as the total amount of short term and long term borrowings repaid and issued.
- Sanofi debt issuance/retirement net - total for the quarter ending March 31, 2025 was $0M, a 0% increase year-over-year.
- Sanofi debt issuance/retirement net - total for the twelve months ending March 31, 2025 was $4.530B, a 219.09% decline year-over-year.
- Sanofi annual debt issuance/retirement net - total for 2024 was $-0.967B, a 71.5% decline from 2023.
- Sanofi annual debt issuance/retirement net - total for 2023 was $-3.394B, a 158.75% increase from 2022.
- Sanofi annual debt issuance/retirement net - total for 2022 was $-1.312B, a 60.46% decline from 2021.
Sanofi Annual Debt Issuance/Retirement Net - Total
(Millions of US $) |
| 2024 |
$-967 |
| 2023 |
$-3,394 |
| 2022 |
$-1,312 |
| 2021 |
$-3,317 |
| 2020 |
$-2,153 |
| 2019 |
$-550 |
| 2018 |
$10,301 |
| 2017 |
$-2,596 |
| 2016 |
$2,537 |
| 2015 |
$1,495 |
| 2014 |
$-500 |
| 2013 |
$796 |
| 2012 |
$-791 |
| 2011 |
$7,560 |
| 2010 |
$-1,960 |
| 2009 |
$3,777 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$128.587B |
$44.458B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
